Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Phathom Pharmaceuticals (PHAT) has announced it will report its third quarter 2024 financial results and provide a business update via live webcast on Thursday, November 7, 2024, at 8:30 am ET. The company, which focuses on developing and commercializing gastrointestinal disease treatments, will make the webcast available through their investor relations website, with a recording accessible for 90 days afterward. Phathom markets VOQUEZNA® tablets for various GERD treatments and H. pylori infection through their VOQUEZNA® TRIPLE PAK® and DUAL PAK® products.
Phathom Pharmaceuticals (PHAT) ha annunciato che riporterà i suoi risultati finanziari del terzo trimestre 2024 e fornirà un aggiornamento aziendale tramite webcast live giovedì 7 novembre 2024, alle 8:30 ET. L'azienda, che si concentra sullo sviluppo e la commercializzazione di trattamenti per le malattie gastrointestinali, renderà disponibile il webcast attraverso il loro sito web per le relazioni con gli investitori, con una registrazione accessibile per 90 giorni dopo. Phathom commercializza le compresse VOQUEZNA® per vari trattamenti del GERD e per l'infezione da H. pylori attraverso i loro prodotti VOQUEZNA® TRIPLE PAK® e DUAL PAK®.
Phathom Pharmaceuticals (PHAT) ha anunciado que reportará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización empresarial a través de una transmisión en vivo el jueves 7 de noviembre de 2024, a las 8:30 am ET. La compañía, que se enfoca en el desarrollo y comercialización de tratamientos para enfermedades gastrointestinales, hará que la transmisión esté disponible a través de su sitio web de relaciones con inversores, con una grabación accesible durante 90 días después. Phathom comercializa tabletas VOQUEZNA® para varios tratamientos de GERD y la infección por H. pylori a través de sus productos VOQUEZNA® TRIPLE PAK® y DUAL PAK®.
Phathom Pharmaceuticals (PHAT)는 2024년 3분기 재무 결과를 보고하고 2024년 11월 7일 목요일 오전 8시 30분 ET에 라이브 웨비나를 통해 비즈니스 업데이트를 제공할 것이라고 발표했습니다. 위장 질환 치료제의 개발과 상업화에 주력하는 이 회사는 투자자 관계 웹사이트를 통해 웨비나를 제공하며, 이후 90일 동안 녹화본을 이용할 수 있습니다. Phathom은 VOQUEZNA® 정제를 다양한 GERD 치료와 H. pylori 감염을 위한 VOQUEZNA® TRIPLE PAK® 및 DUAL PAK® 제품을 통해 판매하고 있습니다.
Phathom Pharmaceuticals (PHAT) a annoncé qu'il présentera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l'entreprise via un webinaire en direct le jeudi 7 novembre 2024, à 8h30 ET. L'entreprise, qui se concentre sur le développement et la commercialisation de traitements pour les maladies gastro-intestinales, mettra le webinaire à disposition sur son site de relations avec les investisseurs, avec un enregistrement accessible pendant 90 jours après. Phathom commercialise des comprimés VOQUEZNA® pour divers traitements de la GERD et des infections à H. pylori à travers ses produits VOQUEZNA® TRIPLE PAK® et DUAL PAK®.
Phathom Pharmaceuticals (PHAT) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 berichten und ein Unternehmensupdate per Live-Webcast am Donnerstag, den 7. November 2024, um 8:30 Uhr ET bereitstellen wird. Das Unternehmen, das sich auf die Entwicklung und Vermarktung von Behandlungen für Magen-Darm-Erkrankungen spezialisiert hat, wird den Webcast über seine Investor Relations-Website zur Verfügung stellen, mit einer Aufzeichnung, die 90 Tage lang zugänglich ist. Phathom vermarktet VOQUEZNA®-Tabletten für verschiedene GERD-Behandlungen und H. pylori-Infektionen über ihre Produkte VOQUEZNA® TRIPLE PAK® und DUAL PAK®.
- None.
- None.
- Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When will Phathom Pharmaceuticals (PHAT) report Q3 2024 earnings?
How can I access Phathom Pharmaceuticals (PHAT) Q3 2024 earnings webcast?
What products does Phathom Pharmaceuticals (PHAT) currently market in the US?
